AsianScientist (Jan. 23, 2012) – GE Global Research, the technology development arm for GE Healthcare, has signed a Memorandum of Understanding (MOU) with Singapore’s Agency of Science, Technology and Research (A*STAR) to develop clinical cancer imaging technologies and diagnostics.
This MOU expands upon another collaboration between GE and A*STAR’s Singapore Bioimaging Consortium (SBIC) using Hyperpolarized Carbon-13 technology, with the goal of improving diagnosis and tissue characterization in diseases that are prevalent in the Asian population, such as liver, lung, and gastric cancers.
As part of the MOU, A*STAR and GE Global Research will collaborate to enhance medical imaging technologies in imaging modalities, ranging from magnetic resonance imaging (MRI) and positron emission tomography (PET) to computed tomography (CT).
In one project, scientists from A*STAR’s Institute of Microelectronics (IME) and GE scientists will explore the development of new imaging technologies to improve the speed and accuracy of clinical cancer diagnosis.
In another project, A*STAR’s Singapore Bioimaging Consortium (SBIC) and GE plan to develop novel imaging markers for hepatic cellular carcinoma (HCC), the most common type of liver cancer in Asia.
——
Source: A*STAR.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
